Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04669496
Status:
RECRUITING
Last Update Posted:
2021-07-07
First Post:
2020-12-14
Brief Title:
Phase II-III Clinical Trial of PD1 Antibody Toripalimab Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-20
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12
Completion Date Type:
ESTIMATED
First Submit Date:
2020-12-14
First Submit QC Date:
December 14 2020
Study First Post Date:
2020-12-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-05
Last Update Post Date:
2021-07-07
Last Update Post Date Type:
ACTUAL